Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2008-05-07 Interim / Quarterly Rep…
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2008
Interim / Quarterly Report Classification · 100% confidence The document is a 'delårsrapport' (interim report) for Orexo AB for the period January-March 2008. It contains comprehensive financial data, including income statements, earnings per share, and detailed management commentary on business performance, clinical trials, and strategic developments. It is a full quarterly report, not an announcement or a summary. Q1 2008
2008-05-07 Swedish
Earnings Release 2008
Earnings Release Classification · 90% confidence The document is titled "Press release April 29, 2008" and details the positive results from a Phase I clinical study for a drug candidate (OX19). It discusses clinical data (uptake, bioavailability), next steps (seeking partnership), and includes standard company boilerplate information. This content is characteristic of an initial announcement of key financial or operational results, rather than a comprehensive annual report (10-K), a detailed interim report (IR), or a formal transcript (CT). Since it announces specific, positive operational/development results, it aligns best with an Earnings Release (ER), which often includes operational highlights alongside financial results, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the format is a 'Press release' announcing study results, ER is the most appropriate fit among the provided options for a significant operational update, even if it's not strictly quarterly earnings. FY 2008
2008-04-29 English
Regulatory Filings 2008
Regulatory Filings Classification · 95% confidence The document is a press release dated April 29, 2008, announcing positive results from a Phase I clinical study for a drug candidate (OX19). It details the study's findings regarding drug absorption and next steps (seeking partnerships for further development). This type of announcement, focusing on clinical trial results and immediate strategic next steps, is characteristic of an Earnings Release (ER) if it were quarterly results, or more generally, a significant corporate/product development update. Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a formal regulatory filing like a DVA or LTR, and it is an announcement of results rather than a presentation (IP) or a transcript (CT), the most fitting category for a press release detailing key operational/development milestones is the Earnings Release (ER) category, which often encompasses key operational highlights outside of formal financial reporting periods, or the general Regulatory Filings (RNS) category. Given the focus on clinical trial success and immediate business strategy (seeking partners), it functions as a key operational update. However, since the definitions prioritize specific financial reports, and this is a product development update, it fits best under the general 'Regulatory Filings' (RNS) as a non-standard announcement, or potentially 'Capital/Financing Update' (CAP) if the partnership search is the main focus, but the core is the study result. Given the options, and that it is a press release announcing a key development, RNS is the safest fallback, but ER often captures these types of operational highlights when they are presented as 'news'. Since it is not explicitly about quarterly earnings but about a specific drug trial, RNS is the most appropriate general regulatory announcement category for non-standard news releases.
2008-04-29 Swedish
M&A Activity 2008
M&A Activity Classification · 99% confidence The document is a press release dated April 14, 2008, announcing a major commercialization rights deal between Orexo and Meda for two drugs (Sublinox and OX-NLA). It details upfront payments, milestone payments, and royalty structures. This type of announcement, concerning significant business transactions, licensing agreements, or major strategic partnerships that affect the company's future operations and financial structure, fits best under the 'Capital/Financing Update' (CAP) category, as it involves a large financial transaction and changes in commercial rights, or potentially 'Regulatory Filings' (RNS) if it were a mandatory disclosure without a better fit. However, given the focus on a multi-million dollar deal structure and milestone payments, 'CAP' is the most specific fit among the provided options for a major transaction announcement that isn't strictly M&A (TAR) or insider trading (DIRS). Since it is a press release announcing a deal structure, and not a formal regulatory filing form, RNS is a strong secondary candidate, but CAP captures the essence of the financial/capital structure change better than the general RNS fallback. Given the options, this is a significant corporate transaction announcement, leaning towards CAP.
2008-04-14 English
M&A Activity 2008
M&A Activity Classification · 95% confidence The document is a press release dated April 14, 2008, announcing a significant business transaction between Orexo and Meda regarding the acquisition of exclusive worldwide rights to two patented Phase III drugs (Sublinox and OX-NLA) by Meda from Orexo. This involves upfront payments, milestone payments, and royalties. This type of announcement details a major corporate transaction, specifically a licensing/acquisition deal concerning drug development rights and associated financial terms. This fits best under 'M&A Activity' (TAR) as it concerns the transfer of significant assets/rights, although it is a licensing deal rather than a full merger or takeover. However, given the options, TAR (Merger/Takeover Activity) is the closest fit for a major corporate transaction involving asset transfer and significant financial consideration, compared to financing (CAP) or general regulatory news (RNS). Since the core event is the transfer of rights for substantial value, TAR is the most appropriate classification among the provided choices.
2008-04-14 Swedish
AGM Information 2008
AGM Information Classification · 99% confidence The document is explicitly titled 'Report from Orexo AB's Annual General Meeting, April 3, 2008'. It details the resolutions passed at the meeting, including the re-election of the Board of Directors, auditor appointments, committee compositions, director fees, and approval of share/warrant plans. This content directly corresponds to the materials presented or decided upon during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length (4892 chars) is substantial enough to be the report itself, not just an announcement of the report (RPA).
2008-04-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.